Wakix (pitolisant) / Bioprojet, Ferrer International, Paragon Biosci, RareStone Group  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wakix (pitolisant) / Ferrer International, Paragon Biosci, Aculys Pharma
NCT04257929: A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Hourglass Jan 2022 - Jun 2022 : Efficacy and safety data for treatment of EDS in patients with Prader Willi syndrome
Active, not recruiting
2
65
US
Pitolisant oral tablets, Placebo oral tablet
Harmony Biosciences, LLC
Prader-Willi Syndrome
08/22
09/28
NCT04886518: Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

Hourglass Jul 2022 - Dec 2022 : Efficacy and safety data for treatment of EDS in patients with Myotonic Dystrophy Type 1
Active, not recruiting
2
30
Canada, US
Pitolisant Oral Tablet, Placebo oral tablet
Harmony Biosciences, LLC
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
10/23
10/24
NCT05953389: Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents

Not yet recruiting
2
62
NA
Pitolisant, BF2.649, Placebo
Bioprojet
Autism Spectrum Disorder
01/25
01/25

Download Options